Piper Sandler keeps Buy rating for Inovio Pharmaceuticals stock at USD 4.00
Published on 10/27/2026 at 20:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and financial position
- Piper Sandler analyst Edward Tenthoff reiterated a Buy rating and set a USD 4.00 target on October 21, 2026.
- Inovio reported a USD 6.01 million GAAP net loss for the second quarter of 2026, compared with USD 23.52 million a year earlier.
- Inovio Pharmaceuticals stock traded at EUR 0.83 at Lang & Schwarz on October 27, 2026 at 8:29 p.m. CET.
On October 21, 2026, Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Inovio Pharmaceuticals and set a USD 4.00 price target, according to Markets Insider. The target lies 334.78 percent above the USD 0.92 Nasdaq price at 3:30 p.m. ET on October 27, 2026.
Analyst support meets a loss
The latest quarterly figures show why the target remains a high-risk proposition. Inovio reported a GAAP net loss of USD 6.01 million for the second quarter of 2026, compared with a USD 23.52 million loss in the second quarter of 2025, as Markets Insider reported.
Stock remains below its yearly high
Inovio's Nasdaq price of USD 0.92 stood within a 52-week range of USD 0.56 to USD 2.72 on October 27, 2026. It was 66.18 percent below the high and 64.29 percent above the low. The company had a market capitalization of USD 63.3 million at that time.
Next earnings date is November 9
The next earnings release is listed for November 9, 2026, according to InvestBamboo. That date gives investors a nearer financial checkpoint than the longer-term analyst target, while the second-quarter loss remains the latest reported earnings figure.
Euro quote after hours
Inovio Pharmaceuticals stock was trading at EUR 0.83 at Lang & Schwarz on October 27, 2026 at 8:29 p.m. CET in after-hours trading. The company operates in biotechnology and develops DNA medicines for infectious diseases, cancer and other conditions.
The further course of trading is shown by the continuously updated real-time quote of Inovio Pharmaceuticals stock.
Inovio Pharmaceuticals at a glance
- Company: Inovio Pharmaceuticals, Inc.
- ISIN: US45773H4092
- Ticker: INO
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 27, 2026, 8:29 p.m. CET): EUR 0.83
- 52-week range: USD 0.56-2.72 (as of October 27, 2026)
- Sector / Industry: Healthcare / Biotechnology
Market context: Market report S&P 500.
